Why low line losses are especially important in early-phase clinical trials
Early-phase clinical programmes often face a different set of challenges compared with late-stage or commercial manufacturing.
Drug substance may be scarce. The formulation may still be evolving. The clinical protocol may require flexibility. The sponsor may need enough finished product for first-in-human studies, dose escalation, cohort expansion, stability, analytical testing and contingency supply.
For this reason, sterile fill-finish strategy needs to be aligned with the realities of early development.
Low line losses can help sponsors:
- maximise the number of finished units from a limited batch
- reduce waste of high-value drug product
- protect scarce API or biologic material
- improve the likelihood of meeting clinical supply targets
- reduce the risk of additional manufacturing runs
- support better planning for stability and retain samples
- protect project timelines
For early-stage biotech companies, the commercial impact can be significant. A small amount of avoidable product loss may represent weeks or months of upstream development work, high API cost, or limited material that cannot be quickly replaced.
The impact of line losses on high-value and complex products
Low line losses are particularly important for products where the drug substance is expensive, difficult to manufacture or available in limited quantities.
This may include:
- biologics and large molecules
- advanced therapies
- cell and gene therapy products
- rare disease medicines
- peptides and oligonucleotides
- radiopharmaceutical cold kits
- high-potency or complex injectables
- early-stage products with limited API availability
In these programmes, the objective is not simply to fill containers. The objective is to preserve as much usable drug product as possible while maintaining sterility, compliance and product quality.
A sterile fill-finish process with low hold-up volume, efficient product transfer and well-controlled filling can help sponsors get more value from the material they have available.
Line losses and clinical supply planning
Line losses are not only a manufacturing efficiency issue. They are also a clinical supply planning issue.
When planning a clinical trial, sponsors need to consider the total number of units required for:
- patient dosing
- screening or dose escalation cohorts
- placebo or comparator requirements
- overage
- stability studies
- analytical testing
- retain samples
- QP certification
- potential resupply
- temperature excursion or shipment contingency
If line losses are higher than expected, the number of finished units available for release may be lower than planned. This can create pressure later in the clinical supply chain.
For early-phase trials, where batch sizes are typically smaller, predictable low line losses can support better planning and reduce the risk of supply shortfalls.
How sterile fill-finish design can reduce line losses
Line losses are influenced by process design, equipment selection, operational control and technical experience.
Key factors include:
1. Facility and equipment design
A sterile fill-finish facility designed for small-batch clinical supply can be configured to reduce unnecessary hold-up volumes and support efficient product movement through the process.
Large-scale commercial filling lines are not always ideal for early-phase products, particularly where batch volumes are small and product value is high.
2. Single-use technologies
Single-use assemblies can support efficient product transfer while reducing cleaning burden and cross-contamination risk. When designed appropriately, they can also help reduce product hold-up and improve process flexibility.
3. Aseptic isolator technology
A Grade A isolator provides a highly controlled aseptic environment while supporting contamination control and operator separation. For clinical sterile fill-finish, isolator-based processing can provide both quality and efficiency advantages.
4. Optimised filling strategy
Line set-up, priming, fill volume control, in-process checks and reject management all influence final yield. A well-planned filling strategy helps ensure that product losses are minimised without compromising quality.
5. Experienced technical oversight
Low line losses are not achieved by equipment alone. They require input from experienced technical, quality and operational teams who understand the relationship between process design, sterility assurance, product yield and clinical supply requirements.
Eramol Aseptic Services
Why low line losses should be part of CDMO selection
When selecting a sterile fill-finish CDMO, sponsors often focus on availability, regulatory status, batch size, container formats and cost.
These are important. But line losses should also be part of the supplier selection conversation.
Sponsors should ask potential sterile fill-finish partners:
- What line losses should we expect for our batch size?
- How is the process designed to minimise product loss?
- What technologies are used to reduce hold-up volume?
- How are filling line start-up and product transfer controlled?
- How much overage should be planned?
- How will the CDMO support yield calculations?
- How will product losses be documented and communicated?
- How does the process support small-batch clinical supply?
For high-value products, the lowest headline manufacturing cost may not represent the best value if the process leads to higher drug product loss.
A CDMO that can protect valuable material, reduce waste and support clinical supply planning may provide stronger overall value to the programme.
Eramol’s approach to low-loss sterile fill-finish
Eramol’s sterile fill-finish service has been designed around the needs of early-phase clinical programmes.
Our approach combines:
- <0.1% aseptic line losses
- Grade A isolator-based aseptic processing
- terminal sterilisation capability
- batch sizes up to 10 L
- fill volumes from 0.5–10 mL
- support for vials, cartridges and pre-filled syringes
- QC testing
- clinical packaging and labelling
- UK and EU QP certification
- temperature-controlled storage
- global distribution
This integrated model allows sponsors to move from sterile fill-finish through to clinical release with fewer handovers and clearer communication.
By combining sterile manufacturing, quality oversight and clinical supply services under one project team, Eramol helps reduce complexity while protecting valuable drug product.
Low line losses support more than yield
Low line losses are often discussed in terms of manufacturing yield, but the benefit goes further.
For clinical-stage sponsors, low line losses can support:
- better use of limited drug substance
- improved clinical supply confidence
- reduced risk of avoidable remanufacture
- stronger alignment between manufacturing output and trial needs
- better project planning
- more efficient use of budget
- faster movement towards clinical release
In early-phase development, where timelines are critical and product availability may be constrained, these benefits can make a meaningful difference.
Eramol Sterile Fill Finish Service
Conclusion
Sterile fill-finish is a critical step in the journey from drug substance to clinical trial supply. For early-phase programmes, the ability to minimise line losses can directly influence product availability, cost efficiency and clinical supply confidence.
When drug product is valuable, scarce or complex, every millilitre matters.
That is why low line losses should be a key consideration when selecting a sterile fill-finish partner.
Eramol’s early-phase sterile fill-finish capability has been designed to support sponsors who need quality, flexibility and product preservation from manufacture through to clinical release.